Search Results Search Sort by RelevanceMost Recent Medicine and Society Sep 2009 Getting Personal with DNA: From Genome to Me-Ome Shane K. Green, PhD and Mike Spear The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves. Virtual Mentor. 2009;11(9):714-720. doi: 10.1001/virtualmentor.2009.11.9.msoc1-0909. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307. In the Literature Jul 2003 Financial Conflicts of Interest in Biomedical Research Jeremy Spevick Virtual Mentor. 2003;194-196. doi: 10.1001/virtualmentor.2003.5.7.jdsc1-0307. Health Law Jul 2003 Is it Legal for a Physician to Receive Payment for Prescribing a Drug? Kristin A. Sorenson Virtual Mentor. 2003;5(7):260-262. doi: 10.1001/virtualmentor.2003.5.7.hlaw1-0307. Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310 Case and Commentary Jun 2016 Medication Refusal in Schizophrenia: Preventive and Reactive Ethical Considerations James Sabin, MD Overriding a proxy decision maker’s refusal of medication for a psychotic patient is justified when the patient poses a danger to himself or others. AMA J Ethics. 2016;18(6):572-578. doi: 10.1001/journalofethics.2016.18.6.ecas1-1606. Case and Commentary Oct 2002 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2002;4(10):288-291. doi: 10.1001/virtualmentor.2002.4.10.ccas1-0210. Case and Commentary Oct 2002 Clinician and Researcher, Commentary 2 Matthew Wynia, MD, MPH Virtual Mentor. 2002;4(10):292-295. doi: 10.1001/virtualmentor.2002.4.10.ccas1-0210. Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Medicine and Society Sep 2009 Getting Personal with DNA: From Genome to Me-Ome Shane K. Green, PhD and Mike Spear The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves. Virtual Mentor. 2009;11(9):714-720. doi: 10.1001/virtualmentor.2009.11.9.msoc1-0909.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2003;5(7):247-250. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
Case and Commentary Jul 2003 Clinician and Researcher, Commentary 2 Matthew Wynia, MD Virtual Mentor. 2003;5(7):251-254. doi: 10.1001/virtualmentor.2003.5.7.ccas2-0307.
In the Literature Jul 2003 Financial Conflicts of Interest in Biomedical Research Jeremy Spevick Virtual Mentor. 2003;194-196. doi: 10.1001/virtualmentor.2003.5.7.jdsc1-0307.
Health Law Jul 2003 Is it Legal for a Physician to Receive Payment for Prescribing a Drug? Kristin A. Sorenson Virtual Mentor. 2003;5(7):260-262. doi: 10.1001/virtualmentor.2003.5.7.hlaw1-0307.
Policy Forum Oct 2003 Psychotropic Medications and Criminal Defendants Robert M. Wettstein, MD Virtual Mentor. 2003;5(10):455-459. doi: 10.1001/virtualmentor.2003.5.10.pfor1-0310
Case and Commentary Jun 2016 Medication Refusal in Schizophrenia: Preventive and Reactive Ethical Considerations James Sabin, MD Overriding a proxy decision maker’s refusal of medication for a psychotic patient is justified when the patient poses a danger to himself or others. AMA J Ethics. 2016;18(6):572-578. doi: 10.1001/journalofethics.2016.18.6.ecas1-1606.
Case and Commentary Oct 2002 Clinician and Researcher, Commentary 1 Timothy F. Murphy, PhD Virtual Mentor. 2002;4(10):288-291. doi: 10.1001/virtualmentor.2002.4.10.ccas1-0210.
Case and Commentary Oct 2002 Clinician and Researcher, Commentary 2 Matthew Wynia, MD, MPH Virtual Mentor. 2002;4(10):292-295. doi: 10.1001/virtualmentor.2002.4.10.ccas1-0210.
Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542.